ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting [Yahoo! Finance]
ProMIS Neurosciences Inc. - Common Shares (PMN)
Company Research
Source: Yahoo! Finance
biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that the Company will present preclinical data on computationally-derived vaccines for neurodegenerative diseases at the American Academy of Neurology (AAN) Annual Meeting taking place from April 5-9, 2025 in San Diego. “We are excited to showcase the potential of our computational modeling platform for developing next-generation novel targeted vaccines to combat neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. “These promising preclinical data support our novel approach for the rational design of vaccines selectively targeting misfolded toxic proteins that drive neurodegenerative diseases. We look forward to advancing our mission to develop safe and effe
Show less
Read more
Impact Snapshot
Event Time:
PMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PMN alerts
High impacting ProMIS Neurosciences Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
PMN
News
- ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s DiseaseGlobeNewswire
- ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA RiskGlobeNewswire
- Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310GlobeNewswire
- ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference [Canadian Business Journal (Canada)]Canadian Business Journal
PMN
Sec Filings
- 12/16/25 - Form 8-K
- 11/24/25 - Form 8-K
- 11/19/25 - Form 8-K
- PMN's page on the SEC website